These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 23131697)
1. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients. Fukuda T; Goebel J; Cox S; Maseck D; Zhang K; Sherbotie JR; Ellis EN; James LP; Ward RM; Vinks AA Ther Drug Monit; 2012 Dec; 34(6):671-9. PubMed ID: 23131697 [TBL] [Abstract][Full Text] [Related]
2. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Baldelli S; Merlini S; Perico N; Nicastri A; Cortinovis M; Gotti E; Remuzzi G; Cattaneo D Pharmacogenomics; 2007 Sep; 8(9):1127-41. PubMed ID: 17924828 [TBL] [Abstract][Full Text] [Related]
3. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. Zhang WX; Chen B; Jin Z; Yu Z; Wang X; Chen H; Mao A; Cai W Xenobiotica; 2008 Nov; 38(11):1422-36. PubMed ID: 18946804 [TBL] [Abstract][Full Text] [Related]
4. Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients. Xie XC; Li J; Wang HY; Li HL; Liu J; Fu Q; Huang JW; Zhu C; Zhong GP; Wang XD; Sun PP; Huang M; Wang CX; Li JL Acta Pharmacol Sin; 2015 May; 36(5):644-50. PubMed ID: 25864649 [TBL] [Abstract][Full Text] [Related]
5. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. van Schaik RH; van Agteren M; de Fijter JW; Hartmann A; Schmidt J; Budde K; Kuypers D; Le Meur Y; van der Werf M; Mamelok R; van Gelder T Clin Pharmacol Ther; 2009 Sep; 86(3):319-27. PubMed ID: 19494809 [TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Naesens M; Kuypers DR; Verbeke K; Vanrenterghem Y Transplantation; 2006 Oct; 82(8):1074-84. PubMed ID: 17060857 [TBL] [Abstract][Full Text] [Related]
7. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Lévesque E; Delage R; Benoit-Biancamano MO; Caron P; Bernard O; Couture F; Guillemette C Clin Pharmacol Ther; 2007 Mar; 81(3):392-400. PubMed ID: 17339869 [TBL] [Abstract][Full Text] [Related]
8. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Kuypers DR; Naesens M; Vermeire S; Vanrenterghem Y Clin Pharmacol Ther; 2005 Oct; 78(4):351-61. PubMed ID: 16198654 [TBL] [Abstract][Full Text] [Related]
9. Study on the association of UGT1A9 gene c.98T>C polymorphism and mycophenolic acid plasma levels in renal transplant patients. Ruschel LR; Schmitt VM; Silva AB; Oliveira CSA; Flach K; d'Avila DO; Thiesen FV Genet Mol Res; 2017 May; 16(2):. PubMed ID: 28613375 [TBL] [Abstract][Full Text] [Related]
10. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Miura M; Kagaya H; Satoh S; Inoue K; Saito M; Habuchi T; Suzuki T Ther Drug Monit; 2008 Oct; 30(5):559-64. PubMed ID: 18695635 [TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study. Ting LS; Benoit-Biancamano MO; Bernard O; Riggs KW; Guillemette C; Ensom MH Pharmacotherapy; 2010 Nov; 30(11):1097-108. PubMed ID: 20973683 [TBL] [Abstract][Full Text] [Related]
12. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Kuypers DR; de Jonge H; Naesens M; de Loor H; Halewijck E; Dekens M; Vanrenterghem Y Clin Ther; 2008 Apr; 30(4):673-83. PubMed ID: 18498916 [TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. Johnson LA; Oetting WS; Basu S; Prausa S; Matas A; Jacobson PA Eur J Clin Pharmacol; 2008 Nov; 64(11):1047-56. PubMed ID: 18568343 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers. Lévesque E; Benoit-Biancamano MO; Delage R; Couture F; Guillemette C Pharmacogenomics; 2008 Jul; 9(7):869-79. PubMed ID: 18597651 [TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Yang JW; Lee PH; Hutchinson IV; Pravica V; Shah T; Min DI Ther Drug Monit; 2009 Oct; 31(5):542-8. PubMed ID: 19730281 [TBL] [Abstract][Full Text] [Related]
16. Regression and Genomic Analyses on the Association Between Dose-Normalized Mycophenolic Acid Exposure and Absolute Neutrophil Count in Steroid-Free, De Novo Kidney Transplant Recipients. Kiang TKL; Partovi N; Shapiro RJ; Berman JM; Collier AC; Ensom MHH Clin Drug Investig; 2018 Nov; 38(11):1011-1022. PubMed ID: 30178220 [TBL] [Abstract][Full Text] [Related]
17. CYP3A5 and UGT1A9 Polymorphisms Influence Immunosuppressive Therapy in Pediatric Kidney Transplant Recipients. Krall P; Yañez D; Rojo A; Delucchi Á; Córdova M; Morales J; Boza P; de la Rivera A; Espinoza N; Armijo N; Castañeda LE; Farfán MJ; Salas C Front Pharmacol; 2021; 12():653525. PubMed ID: 33967795 [No Abstract] [Full Text] [Related]
18. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Kagaya H; Inoue K; Miura M; Satoh S; Saito M; Tada H; Habuchi T; Suzuki T Eur J Clin Pharmacol; 2007 Mar; 63(3):279-88. PubMed ID: 17211619 [TBL] [Abstract][Full Text] [Related]
19. Influence of uridine diphosphate-glucuronosyltransferases (1A9) polymorphisms on mycophenolic acid pharmacokinetics in patients with renal transplant. Ciftci HS; Demir E; Karadeniz MS; Tefik T; Nane I; Oguz FS; Aydin F; Turkmen A Ren Fail; 2018 Nov; 40(1):395-402. PubMed ID: 30012031 [TBL] [Abstract][Full Text] [Related]
20. Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Inoue K; Miura M; Satoh S; Kagaya H; Saito M; Habuchi T; Suzuki T Ther Drug Monit; 2007 Jun; 29(3):299-304. PubMed ID: 17529886 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]